Without tax reform, pharma M&A's still sluggish—but biotech's red hot
admin 20th October 2017 Uncategorised 0Back when the year began, the prospect of U.S. tax reform had pharma companies salivating for some M&A action. But with that reform still absent, dealmaking in 2017 has so far seen a slowdown.
More: Without tax reform, pharma M&A's still sluggish—but biotech's red hot
Source: fierce